German biotech report: sector grows despite financial crisis


Berlin/Chicago – Despite the financial crisis, the German biotechnology sector grew in the last year. According to a brand-new biotech-report commissioned by the German Research Ministry and published just a couple of days before BIO (Chicago, 3-6 June), Germany’s biotech firms increased employment by 5% to a total of 31.600 jobs (more...). Additionally, the number of biotech companies grew by 6% while revenues remained stable at EUR2.2bn, as in 2008. The report, conducted by (with a response rate of over 80% from the companies) provides an excellent source of internationally comparable figures, at it covers all biotech companies active in Germany and is compliant to the OECD biotechnology guidelines. In 2009, there were 531 dedicated biotechnology companies, an increase of 12 firms compared to 2008 and employing 14,950 staff (2008: 14,450). Additionally, the number of companies, in which biotech was only one aspect of business activity, grew from 92 to 114 enterprises, with 16,650 staff (2008: 15,520). The dedicated biotechnology firms had 8 drugs on the market and 102 under clinical development, had invested EUR1bn into R&D and received funding of EUR51m, the same amount as in the year before the financial crisis. However, while public companies increased their capital by EUR122m (+32% as compared to 2008), VC money was difficult to obtain for the most biotech SMEs. VC investments decreased by 30% compared to 2008 and achieved only EUR142m. "German biotech companies have shown tremendous robustness in the economic crisis. Many companies have adapted to the difficult financial environment and reduced their loss, mainly by establishing a profitable service business," said Boris Mannhardt, PhD, Director of Studies of and responsible for the annual survey.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week



All videos


All Events

Stock list

All quotes


  • ANALYTIK JENA14.00 EUR0.07%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%


  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%


  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%


  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%


  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%


  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 28.03.2015

Current issue

All issues